Arkolith/Insider Trading/CGEM/Form 4

Fenton Mary Kay

Chief Financial OfficerCullinan Therapeutics, Inc. (CGEM) · full profile →Form 4 · filed Jan 5, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 31, 2025Grant(A)27$6.49$17562K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-002687) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML